Emanuele F Osimo
Overview
Explore the profile of Emanuele F Osimo including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
604
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Formanek T, Krupchanka D, Perry B, Mlada K, Osimo E, Masopust J, et al.
Br J Psychiatry
. 2024 Aug;
225(4):436-445.
PMID: 39115008
Background: It remains unknown whether severe mental disorders contribute to fatally harmful effects of physical illness. Aims: To investigate the risk of all-cause death and loss of life-years following the...
2.
Tse W, Khandaker G, Zhou H, Luo H, Yan W, Siu M, et al.
Lancet Reg Health West Pac
. 2024 May;
47:101089.
PMID: 38774423
Background: Metabolic syndrome (MetS) is common following first-episode psychosis (FEP), contributing to substantial morbidity and mortality. The Psychosis Metabolic Risk Calculator (PsyMetRiC), a risk prediction algorithm for MetS following a...
3.
Oliver D, Arribas M, Perry B, Whiting D, Blackman G, Krakowski K, et al.
Biol Psychiatry
. 2024 Feb;
96(7):532-542.
PMID: 38408535
The use of clinical prediction models to produce individualized risk estimates can facilitate the implementation of precision psychiatry. As a source of data from large, clinically representative patient samples, electronic...
4.
Osimo E, Perry B, Mallikarjun P, Pritchard M, Lewis J, Katunda A, et al.
Nat Ment Health
. 2023 Apr;
1(1):25-35.
PMID: 37034013
Around a quarter of people who experience a first episode of psychosis (FEP) will develop treatment-resistant schizophrenia (TRS), but there are currently no established clinically useful methods to predict this...
5.
Osimo E, Perry B, Murray G
Int Clin Psychopharmacol
. 2023 Mar;
38(3):179-181.
PMID: 36947405
No abstract available.
6.
Pillinger T, Osimo E, de Marvao A, Shah M, Francis C, Huang J, et al.
Lancet Psychiatry
. 2023 Jan;
10(2):98-107.
PMID: 36632818
Background: Cardiovascular disease is a major cause of excess mortality in people with schizophrenia. Several factors are responsible, including lifestyle and metabolic effects of antipsychotics. However, variations in cardiac structure...
7.
Perry B, Vandenberghe F, Garrido-Torres N, Osimo E, Piras M, Vazquez-Bourgon J, et al.
Lancet Reg Health Eur
. 2022 Aug;
22:100493.
PMID: 36039146
Background: Cardiometabolic dysfunction is common in young people with psychosis. Recently, the Psychosis Metabolic Risk Calculator (PsyMetRiC) was developed and externally validated in the UK, predicting up-to six-year risk of...
8.
Osimo E, Lewis J, Cardinal R, Khandaker G
BJPsych Open
. 2022 Jul;
8(4):e131.
PMID: 35815763
The antipsychotic clozapine is known to have immune-modulating effects. Clozapine treatment has been reported to be associated with increased risk of COVID-19 infection. However, it remains unclear whether this is...
9.
Osimo E, Brugger S, Thomas E, Howes O
Schizophrenia (Heidelb)
. 2022 Mar;
8(1):24.
PMID: 35304889
People with schizophrenia show higher risk for abdominal obesity than the general population, which could contribute to excess mortality. However, it is unclear whether this is driven by alterations in...
10.
Osimo E, Sweeney M, de Marvao A, Berry A, Statton B, Perry B, et al.
Transl Psychiatry
. 2021 Dec;
11(1):614.
PMID: 34873143
Cardiovascular diseases are the leading cause of death in schizophrenia. Patients with schizophrenia show evidence of concentric cardiac remodelling (CCR), defined as an increase in left-ventricular mass over end-diastolic volumes....